About
Alpex Acquisition Corporation (ALPX)
Alpex Acquisition Corporation focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2026 and is based in Wilmington, Delaware.
The company profile, business description, and key company details are provided by S&P Global Market Intelligence. The list of executives is sourced from SEC.gov. Recent SEC filings are sourced directly from SEC.gov.
Alpex Acquisition Corporation (ALPX) Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:ALPXU
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | $10.01 | $10.02 | $10.01 | $10.02 | $10.02 | +0.01 | 135,800 |
| 2026-06-26 | $10.00 | $10.01 | $9.99 | $9.99 | $9.99 | -0.01 | 597,000 |
| 2026-06-25 | $10.01 | $10.02 | $10.00 | $10.00 | $10.00 | -0.01 | 3,979,400 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| 8-K | Jun 29, 2026 | Current Report |
| 424B4 | Jun 25, 2026 | Prospectus |
| EFFECT | Jun 24, 2026 | Notice of Effectiveness |
| CERT | Jun 24, 2026 | Certification by an exchange approving securities for listing |
| 8-A12B | Jun 24, 2026 | Registration of securities |
| S-1/A | Jun 5, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1/A | May 22, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1 | Apr 10, 2026 | General form for registration of securities under the Securities Act of 1933 |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Daniel R Vlock, MD
President, Chief Executive Officer and Director
Thomas T. Thomas
Chief Financial Officer
Gerald B. Pier, PhD
Chief Scientific Officer
William W. Chin, MD
Senior Strategic Advisor, Director
Christine de los Reyes, PharmD, MBA
Chief Business Officer, Chief Commercialization Officer
Peter J. Werth
Director
